US stem cell clinics, patient safety, and the FDA.

US stem cell clinics, patient safety, and the FDA.

Item
http://www.wikidata.org/entity/Q38461913
Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements.Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.Role of Nursing Competencies for Accelerating Clinical Trials in Stem Cell Clinics.Identity and ownership issues in the regulation of autologous cells.Regulated and Unregulated Clinical Trials of Stem Cell Therapies for Stroke.The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis.The Global Emergence of Unregulated Stem Cell Treatments for Respiratory Diseases. Professional Societies Need to Act.Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions
P2860

US stem cell clinics, patient safety, and the FDA.

Item
http://www.wikidata.org/entity/Q38461913
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
US stem cell clinics, patient safety, and the FDA.
@en
type
label
US stem cell clinics, patient safety, and the FDA.
@en
prefLabel
US stem cell clinics, patient safety, and the FDA.
@en
P1433
P1476
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
US stem cell clinics, patient safety, and the FDA.
@en
P304
P31
P356
10.1016/J.MOLMED.2015.02.008
P433
P478
P50
P577
P698